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The myofibrils of cross-striated muscle fibers contain in their M bands cytoskeletal
proteins whose main function seems to be the stabilization of the three-dimensional
arrangement of thick filaments. We identified two immunoglobin domains (Mp2–Mp3)
of M-protein as a site binding to the central region of light meromyosin. This binding is
regulated in vitro by phosphorylation of a single serine residue (Ser76) in the immedi-
ately adjacent amino-terminal domain Mp1. M-protein phosphorylation by cAMP-de-
pendent kinase A inhibits binding to myosin LMM. Transient transfection studies of
cultured cells revealed that the myosin-binding site seems involved in the targeting of
M-protein to its location in the myofibril. Using the same method, a second myofibril-
binding site was uncovered in domains Mp9–Mp13. These results support the view that
specific phosphorylation events could be also important for the control of sarcomeric M
band formation and remodeling.
INTRODUCTION
Thick and thin myofilaments, the major structural and
functional entities of cross-striated myofibrils, are kept
in their remarkably stable and regular arrangement by
a highly complex cytoskeleton (see, for example, re-
view by Small et al., 1992). While thin filaments are
organized by the Z-discs, the hexagonal thick filament
lattice seems cross-linked in the central bare zone by
bridging structures, the so-called M-bridges and M-
filaments (Luther and Squire, 1978).
Until now, only a small group of proteins has been
shown to be true M band constituents. MM creatine
kinase is thought to be the component that makes up
the M4-M49 bridges (Wallimann et al., 1983; Walli-
mann and Eppenberger, 1985). It is not yet clear
whether, in addition to its obvious role in energy
metabolism, MM creatine kinase is also involved in
the linkage of thick filaments. Three structural pro-
teins were revealed as true M band constituents: M-
protein (Masaki and Takaiti, 1974), myomesin (Grove
et al., 1984), and titin (Nave et al., 1989; Vinkemeier et
al., 1993). Immunofluorescence studies revealed strik-
ing differences in embryonic expression patterns of
these proteins: while both titin and myomesin are
expressed from the earliest stages of myocyte differ-
entiation (Grove et al., 1985; Fu¨rst et al., 1989; Carlsson
et al., 1990), M-protein shows a stage- and tissue-
specific distinct redistribution. First, M-protein is tran-
siently expressed in all fetal cross-striated muscle fi-
bers. It is subsequently suppressed in skeletal muscle
fibers around birth and finally is reexpressed in adult
type-II fibers (Grove et al., 1985, 1987; Carlsson et al.,
1990). Recently, the use of a panel of sequence-as-
signed antibodies in immunoelectron microscopy al-
lowed the proposal of a structural model that de-
scribes the layout of titin, myomesin, and M-protein in
the sarcomeric M band. Both titin and myomesin are
arranged largely in an antiparallel and staggered man-
ner, while M-protein seems to bridge the thick fila-
ments essentially in a perpendicular direction (Ober-
mann et al., 1996).
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Although M-protein has been known for a long time
and protocols for its purification did exist, it has been
remarkably difficult to describe, at the molecular level,
its binding to other myofibrillar proteins. Studies per-
formed independently by three different groups con-
cluded “that such interactions are either weak or ab-
sent in vitro” (Mani and Kay, 1978; Woodhead and
Lowey, 1983; Ba¨hler et al., 1985). We addressed this
question by producing a panel of recombinant M-
protein and myosin-rod fragments. Purified recombi-
nant proteins were subsequently used to search for
respective binding sites. These experiments identified
M-protein domains Mp2 to Mp3 as myosin-binding
site and showed that this interaction can be regulated
by phosphorylation.
MATERIALS AND METHODS
Expression of M-Protein Fragments in Escherichia
coli
Partial M-protein sequences were amplified by polymerase chain
reaction (PCR) (Saiki et al., 1985) using the full-length human cDNA
(Vinkemeier et al., 1993) as a template. PCR products were cloned
into a pET23a vector derivative. This provided the recombinant
protein fragments with a carboxy-terminally located His6 sequence
followed by an EEF-tag that can be detected with a monoclonal
antibody. Subsequent to growth of E. coli BL21(DE3)pLysS cells
(Studier et al., 1990) at OD600 5 1.0 in LB medium supplemented
with 2% glucose, 100 mg/ml ampicillin, and 34 mg/ml chloram-
phenicol and induction for 4 h at 18°C with 0.15 mM IPTG1, bacteria
were harvested and stored at 270°C until use. Pellets were resus-
pended and sonicated in buffer A (50 mM potassium phosphate, pH
8.0, 500 mM KCl, 0.2% Tween-20, 5 mM 2-mercaptoethanol) con-
taining 5 mM E64 and 1 mM PMSF as protease inhibitors. After
centrifugation at 16,000 3 g, soluble recombinant proteins were
enriched by metal chelate affinity chromatography. Briefly, protein
solutions were applied onto Ni-NTA-agarose columns (Qiagen,
Hilden, Germany), which were washed with buffer A and subse-
quently with buffer B (same as buffer A, except pH 6.0). Finally, the
recombinant proteins were eluted with 500 mM imidazole in buffer
B. After dialysis against buffer C (50 mM Tris-HCl, pH 7.9, 1 mM
EDTA, 1 mM DTT) recombinant proteins were purified to homoge-
neity by ion exchange chromatography on MonoQ FPLC columns
(Pharmacia, Uppsala, Sweden). Integrity of the purified proteins
was monitored by N-terminal sequencing and the reaction with the
EEF-tag specific antibody YL1/2 (Wehland et al., 1984).
Mutagenesis
Serine to alanine mutations were introduced into the M-protein
Mp1–5 fragment by PCR amplification with mismatch oligonucleo-
tides resulting in site-directed exchanges of serine to alanine codons
following the method of Ausubel et al., 1995). Amplified fragments
were subcloned into pET-23a- derived expression vectors and the
eukaryotic expression vector pCMV5/T7 (see below). DNA se-
quencing established the original sequence and the desired Ser/Ala
exchanges.
Recombinant Fragments of Myosin
Different portions of rabbit fast skeletal muscle LMM were ampli-
fied by PCR using the original cDNA of rabbit myosin heavy
chain-2/10 (Maeda et al., 1987) as a template. Four constructs were
designed, in which the carboxy termini were identical with the end
of the original clone (i.e., amino acid residue 1939). The amino
termini were placed at different points along the sequence of the
myosin rod portion. This resulted in a series of “shorter LMMs,”
which were designated according to their approximate molecular
masses (in kilodaltons): LMM75 (corresponding to residues 1284–
1939 of the original clone; Maeda et al., 1987), LMM59 (residues
1429–1939), LMM50 (residues 1506–1939), and LMM30 (residues
1675–1939). In addition, a construct, called LMM75–50, was made. It
corresponds to the amino-terminal portion of LMM and represents
residues 1284–1505 of the myosin heavy chain sequence. For the
positions of these constructs on the myosin rod, see also the sche-
matic representation in Figure 1. PCR products were cloned into the
pET-23a expression vector (Novagen, Heidelberg, Germany).
Recombinant LMM fragments were expressed in E. coli
BL21(DE3)pLysS and purified by two high-salt/low-salt extraction
and precipitation cycles as described (Maeda et al., 1987). All recom-
binant LMM fragments formed normal paracrystals as judged by
electron microscopic inspection after negative staining (our unpub-
lished results; Maeda et al., 1987).
Preparation of Native Proteins from Bovine Skeletal
Muscle
Myosin rod and LMM were prepared as described (Obermann et al.,
1995). Purification of bovine M-protein was performed as reported
(Vinkemeier et al., 1993). Preparation of proteolytic M-protein frag-
ments obtained by endoproteinase Asp-N, endoproteinase Lys-C,
and trypsin was as described for myomesin (Obermann et al., 1995).
Digests were stopped by the addition of PMSF (endoproteinase
Lys-C and trypsin) or EDTA (endoproteinase Asp-N). Resulting
peptides were separated by gel permeation chromatography using
a Superose 12 HR 10/30 FPLC column equilibrated in 50 mM
Tris-HCl, pH 7.9, 500 mM KCl, 1 mM EDTA, and 1 mM DTT.
Phosphorylation of Proteins and Synthetic Peptides
Purified M-protein as well as its proteolytic trypsin fragment and
recombinant M-protein fragments were added at a final concentra-
tion of 0.2 mg/ml to 20 ml of assay buffer (50 mM MES, pH 6.9, 100
mM KCl, 2 mM MgCl2). Phosphorylation reactions were at 30°C for
30 min with 1 U protein kinase A from porcine heart (Sigma Chem-
ical, St. Louis, MO) or 1 ml of muscle extract and 1 mCi [g-32P]ATP
(3000 Ci/mmol, Amersham, Arlington Heights, IL). After addition
of sample buffer (Laemmli, 1970) and heating to 65°C for 10 min,
polypeptides were analyzed by 4–12% or 6–20% SDS-PAGE. Gels
were dried, and autoradiography was performed at 280°C with
intensifying screens. For a quantification of the phosphorylation,
bands from individual assays were cut out of the gels and homog-
enized. Gel fragments were suspended in “Ready Safe” (Beckman,
Fullerton, CA) and measured in a Beckman LS 8100 liquid scintil-
lation counter. Means of the incorporated counts were calculated
from three independent experiments.
Synthetic peptides were phosphorylated for kinetic experiments
essentially as described previously (Kemp et al., 1977). Briefly, the
reaction mixture (total volume, 70 ml) contained the respective
peptide at concentrations ranging from 0.1 to 1.5 mM in the follow-
ing solution: 10 mCi [g-32P]ATP (0.5 mM), 62.5 mM MES, pH 6.9,
12.5 mM magnesium acetate, 0.25 mM EGTA, and either protein
kinase A (catalytic subunit, Boehringer, Mannheim, Germany) or
sarcomeric muscle extracts prepared as described previously (Ober-
mann et al., 1997). Subsequent to incubation at 37°C for 0, 1, 2, 5, 10,
and 15 min, 8-ml aliquots were removed from the reaction and
phosphorylated peptides were separated from [g-32P]ATP by the
phosphocellulose binding technique (Casnellie, 1991). Apparent Km
1 Abbreviations used: DTT, dithiothreitol; E64, trans-epoxysucci-
nyl-L-leucylamido-(4-guanidino) butane; IPTG, isopropyl
b-d[R]-Thiogalactopyranoside; LMM, light meromyosin; MES,
2-[N-morpholino] ethane sulfonic acid; PKA, cAMP-dependent
protein kinase A; PMSF, phenylmethylsulfonyl fluoride.
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and Vmax values were determined by fitting the data of a double-
reciprocal Lineweaver-Burk plot to the Michaelis-Menten equation
using the method of least squares.
Phosphoamino Acid Analysis
32P-labeled protein was recovered from sample buffer by the
method of Wessel and Flu¨gge (1984), dried, and hydrolyzed in 6 M
HCl at 110°C for 2 h. After lyophylization the hydrolysate was
dissolved in 10 ml H2O and applied to a Polygram CEL400 Uni layer
plate (Merck, Darmstadt, Germany). Electrophoretic separation of
phosphoamino acids was in 10% acetic acid, 1% pyridin, pH 3.5, at
800 V for 1 h. Radioactively labeled phosphoamino acids were
identified by visualization of standard phosphoamino acids with
ninhydrin and autoradiography.
Myosin-binding Assays
M-protein was treated with endoproteinase Asp-N (see above), and
the digest was subjected to gel filtration on a Superose 12 HR10/30
column. One microliter of each fraction was spotted onto nitrocel-
lulose membranes (BA 85, Schleicher & Schu¨ll, Dassel, Germany).
After air drying, the strips were blocked with overlay buffer (1%
BSA, 0.2% Tween 20, 100 mM KCl, 20 mM imidazole-HCl pH 7.0, 1
mM DTT) for 30 min. Purified LMM and recombinant LMM-30
were biotinylated (NHS-LC-Biotinylation kit, Pierce, Rockford
Chemical, Rockford, IL) following the instructions of the manufac-
turer, diluted to 0.1 mg/ml in overlay buffer, and used to treat the
blocked strips for 60 min. After three washes with overlay buffer,
the strips were incubated for 30 min with an avidin-biotin-peroxi-
dase complex (ABC Peroxidase staining kit, Pierce). After a final
washing cycle, binding of LMM to M-protein fragments was visu-
alized by reaction in 5 ml of 100 mM Tris-HCl, pH 7.5, supple-
mented with 100 ml diaminobenzidine (40 mg/ml stock), 25 ml NiCl2
(80 mg/ml stock), and 1.5 ml 30% H2O2. All steps were carried out
at room temperature.
In the case of recombinant M-protein fragments, both a-chymot-
ryptic myosin subfragments (myosin rod and LMM) and recombi-
nant LMM fragments (LMM75, LMM59, LMM50, LMM50–75,
LMM30) were dialyzed to 50 mM KCl, 5 mM Na-phosphate, pH 7.0,
to allow the formation of filaments. Approximately 1 mg of each
suspension was spotted onto nitrocellulose membranes. All subse-
quent steps were as described above expect that individual strips
were incubated for 60 min with the respective M-protein fragments
dissolved in overlay buffer, and detection was with rat monoclonal
antibody YL1/2 (Wehland et al., 1984) specific for the EEF-tag of our
recombinant fragments (see Obermann et al., 1997).
Construction of the pCMV5-T7 Vector and of
Recombinant Constructs
pCMV5 vector was a generous gift from Dr. V. Gerke (MPI, Go¨ttin-
gen). Its polycloning site was excised by digestion with restriction
enzymes EcoRI and SmaI and was replaced by a new cassette con-
taining, from 59 to 39, the following restriction enzyme sites: BamHI,
MluI, HindIII, SalI. This polylinker was followed by a sequence
encoding the 12-amino acids long T7-tag MASMTGGQQMGR
(Lutz-Freyermuth et al., 1990; Tsai et al., 1992) and an in-frame stop
codon. The T7-tag peptide is recognized by a specific monoclonal
antibody that was purchased from Novagen (Heidelberg, Germany)
Desired M-protein fragments were amplified by PCR (Saiki et al.,
1985) using sense primers containing an MluI site and antisense
primers containing a SalI site adjacent to a matching sequence of 30
bp derived from the human cDNA (Vinkemeier et al., 1993). Result-
ing PCR fragments were double digested with MluI and SalI and
ligated to the correspondingly cut pCMV5-T7 vector following stan-
dard protocols (Sambrook et al., 1989). Plasmids were propagated in
JM 109 bacteria, and the DNA was purified on Qiagen columns
(Qiagen, Hilden, Germany).
Cell Culture and Transfections
BHK-21/C13 and C2C12 cells were cultured in DMEM supple-
mented with 2 mM L-glutamine, antibiotics (100 U/ml penicillin
and 1 mg/ml streptomycin), and 10% FCS (BHK) or 15% FCS
(C2C12), all from Life Technologies (Eggenstein, Germany). Ap-
proximately 8 h before transfection, cells were seeded on glass
coverslips at a density that resulted in 40–50% confluency at the
time of transfection. The cells were transfected with the recombinant
pCMV5/T7 constructs using a modification of the calcium phos-
phate precipitation method (Sambrook et al., 1989). Briefly, after
incubation with the transfection mixture for 16 h, the cells were
washed with PBS and glycerol shocked for 2 min using 15% glycerol
in culture medium. Fresh medium was subsequently added. At
different time intervals after transfection, cells were fixed for 10 min
in 3% paraformaldehyde in PBS and permeabilized for 10 min in
0.5% Triton X-100 in PBS. After being rinsed with PBS, the speci-
mens were used in immunofluorescence assays or stored in PBS at
4°C until use. Alternatively, the culture medium was replaced by a
low-nutrition medium (DMEM, L-glutamine and antibiotics as
above, and 0.4% Ultroser G [Life Technologies]), to induce differ-
entiation in both cell types. Between 1 and 6 d after this medium
change, cells were fixed and permeabilized as described above.
Immunohistochemistry
Fixed and permeabilized transfected cells were rinsed with PBS/
0.05% Tween 20 (PBST) and incubated with an antibody directed
against the T7 tag (immunoglobin G2b [IgG2b]; Novagen). In some
experiments the cells were double-stained using standard proce-
dures (Van der Ven et al., 1993) with the T7 tag antibody and an
M-protein domain-specific antibody (MpAA259, IgA: Obermann et
al., 1996), a titin antibody (9D10, IgM: Wang and Greaser, 1985), or
tetramethylrhodamine-5-isothiocyanate-conjugated phalloidin (Sig-
ma, Deisenhofen, Germany) to identify F-actin. The appropriate Ig
subtype-specific fluorescein isothiocyanate- or Texas Red-conju-
gated secondary antibodies were purchased from Southern Biotech-
nology Associates (Birmingham, AL). They were diluted in PBST
according to the recommendations of the manufacturer.
Miscellaneous Procedures
Protein concentrations were determined with the Bio-Rad dye re-
agent (Bio-Rad, Richmond, CA). Synthetic peptides were obtained
by Fmoc chemistry on a Pep Synthesizer TM9050 (Millipore, Bed-
ford, MA). Microsequencing was done as reported (Obermann, et
al., 1995). All DNA cloning steps followed standard protocols (Aus-
ubel et al., 1995, Sambrook et al., 1989). SDS-PAGE and immuno-
blotting were as described previously (Fu¨rst et al., 1988).
RESULTS
M-protein Domains Mp1 to Mp2 Interact with
Myosin Filaments in Vitro
To locate the myosin-binding site of M-protein, we
used limited proteolysis of the purified bovine protein
to produce defined subfragments. Most revealing was
cleavage with endoproteinase AspN, which provided
a ;45-kDa fragment and a ;110-kDa fragment (ar-
rows in Figure 2A). Microsequencing located their
amino termini to Glu136 and Glu496 of the translated
human cDNA sequence. Thus, the 45-kDa fragment
comprises essentially domains Mp2 to Mp4, and the
110-kDa fragment covers the carboxy-terminally situ-
ated remainder of the molecule (for domain designa-
tions see sketch in Figure 1). The two fragments were
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separated by gel filtration chromatography (Figure
2A). Column fractions were used in solid-phase over-
lay assays to investigate the interaction of the frag-
ments with myosin rod and LMM-30. Clearly, only the
smaller, amino-terminally situated 45-kDa fragment of
M-protein (residues 147–496) exhibited binding to
myosin (Figure 2B).
For a more precise mapping of mutual binding sites
in M-protein and myosin, we produced a series of
recombinant M-protein constructs as well as proteo-
lytic and recombinant derivatives of myosin. The
sketch in Figure 1 describes the location of all the
constructs of the two proteins used in this study.
Figure 3A monitors the purity of the M-protein frag-
ments, while the purity of the myosin derivatives was
described recently (Obermann et al., 1997). Several
constructs representing distinct portions of the Mp2 to
Mp4 region of M-protein were employed in solid-
phase myosin-binding assays. Figure 3B shows that
only a fragment comprising the two Ig domains Mp2–
Mp3 exhibited a concentration-dependent interaction
with myosin. In contrast, none of the single domains
was able to bind to myosin. Since in the Mp2 construct
the linker region connecting the domains Mp2 and
Mp3 was contained, we can also exclude the possibil-
ity that this linker alone could constitute the binding
site. This suggests that the two M-protein domains
Mp2–Mp3 constitute the minimal myosin-binding site
of M-protein.
M-protein Is Phosphorylated by PKA in the Amino-
terminal Domain Mp1
M-protein bears a unique amino-terminal domain
(Mp1; 151 residues) and 12 repeat domains of either
the Ig cII and fibronectin type III class (Vinkemeier, et
al., 1993). Detailed computer analysis of the translated
human cDNA sequence predicted two target sites for
cAMP-dependent PKA: Ser39 in the motif KKRAS and
Ser76 in the sequence KRVS. To analyze whether one
or both of these serine residues can be phosphorylated
in the native protein, we incubated purified bovine
M-protein with PKA in the presence of [g-32P]ATP.
Figure 4 documents the phosphorylation of M-protein
by PKA (Figure 4A, lane 1, and Figure 4B, lane 1). For
a preliminary mapping of the phosphorylation site(s),
we subjected M-protein to limited proteolysis by tryp-
sin and isolated a stable fragment comprising domains
Mp6–Mp13 (established by microsequencing). Since
this fragment cannot be phosphorylated by PKA (Fig-
ure 4B), the phosphorylation site(s) must lie in Mp1–
Mp5. Furthermore, we used a digest of M-protein with
endoproteinase AspN. This yielded two fragments
comprising domains Mp2–Mp4 and Mp5–Mp13, re-
spectively (see Figure 2A). Since neither fragment can
be phosphorylated, we concluded that the phosphor-
ylation site must be located in the unique amino ter-
minus and possibly involves the predicted sites in
domain Mp1 (Figure 4, A and B). Phosphoamino acid
analysis of radiolabeled purified M-protein demon-
Figure 1. Summary diagram giv-
ing a schematic representation of
the domain organizations for M-
protein and for myosin. The pre-
sentation emphasizes the modular
construction of M-protein from re-
petitive Ig cII (cross-hatched re-
ctangles) and fibronectin type III
repeats (shaded rectangles) inter-
spersed by unique sequence
stretches of varying length. Recom-
binant constructs used for mapping
of binding sites, transfection of cul-
tured myoblasts, and phosphoryla-
tion assays are marked by brackets.
The location of the most prominent
proteolytic fragments of myosin is
given in the lower panel above the
myosin sketch. Brackets indicate
the borders of the recombinant
LMM constructs used in this study.
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strated that phosphorylation occurs exclusively on
serine (Figure 4C).
For a detailed kinetic characterization of the poten-
tial PKA phosphorylation sites, we synthesized two
peptides: LDEYASKKRASTQASSQ, corresponding to
residues 29–45 of the human sequence, and RVCAK-
RVSTQEDEEQE, comprising residues 69–84 (Vinke-
meier, et al., 1993). Both peptides were efficiently phos-
phorylated by PKA. The kinetics of the reaction were
compared with the kinetics of the liver pyruvate ki-
nase peptide LRRASLG (“kemptide”; Kemp et al.,
1977) and a peptide from a region in myomesin, which
is also phosphorylated by PKA (EKARLKSRPSAP-
WTGQ; Obermann et al., 1997). Table 1 shows that KM
values of both M-protein peptides were ;1000 mM,
which is approximately twice the KM of the myomesin
peptide. The Vmax was not determined in absolute
numbers, since the concentration of PKA in the com-
mercially available preparations could not be mea-
sured. Therefore, the numbers in Table 1 give relative
units. Thus, the Vmax for the phosphorylation of the
first M-protein peptide (LDEYASKKRASTQASSQ) is
;30% of that of the myomesin peptide reaction, while
the Vmax for the second M-protein peptide (RVCAK-
RVSTQEDEEQE) is ;50%.
To examine whether both sites are similarly recog-
nized in the native M-protein molecule, several recom-
binant constructs were made in which either one
(Ser39, Ser76) or both serine residues were mutated to
alanine. Since the amino-terminal domain Mp1 alone
remained entirely insoluble after expression in E. coli,
larger constructs comprising domains Mp1–Mp5 were
used. All recombinant proteins expressed in E. coli
Figure 2. Binding of M-protein and its proteolytic 45-kDa frag-
ment to myosin rod. (A) SDS-PAGE analysis (4–14%) of M-protein
purified from bovine skeletal muscle (lane 1) and gel filtration
fractions of an endoproteinase Asp-N digest of M-protein (see MA-
TERIALS AND METHODS) (lanes 2–12). M 5 molecular mass
standards in kilodaltons. (B) M-protein (1) and corresponding frac-
tions of the M-protein digest (2–12) spotted on nitrocellulose filters
after incubation with biotinylated myosin-rod or LMM 30. Note that
only native M-protein (1) and its 45-kDa fragment (comprising
domains Mp2–Mp4; fractions 9–11) show binding to myosin rod,
while the proteolytic 110-kDa fragment of M-protein (comprising
domains Mp5–Mp13; lanes 2–6) does not bind to myosin rod (the
positions of these proteolytic fragments are indicated by arrows).
Note also that both M-protein fragments do not bind to LMM30.
Thus myosin rod binding of M-protein requires domains Mp2–Mp4. Figure 3. Binding of recombinant M-protein fragments to proteo-
lytic and recombinant derivatives of myosin. (A) SDS-PAGE anal-
ysis (6–20% gradient gels) of purified recombinant M-protein frag-
ments: Mp2 (lane 1), Mp2–Mp3 (lane 2), Mp3 (lane 3), and Mp4 (lane
4). M 5 molecular mass standards in kilodaltons. For domain struc-
ture of M-protein see Figure 1. (B) Results of binding assays. The
same amounts (ca. 1 mg) of myosin rod, proteolytic LMM, LMM 75,
LMM 59, LMM 50, LMM 30, LMM 50–75, and ovalbumin, serving
as a control, were spotted on nitrocellulose filters and overlaid with
increasing concentrations (1 5 0.5 mM, 2 5 1.5 mM, 3 5 4.5 mM) of
M-protein fragments Mp2 (a), Mp2 to Mp3 (b), Mp3 (c), and Mp4
(d). (e) Control without protein in the overlay buffer. Binding of
M-protein fragments carrying the carboxy-terminal EEF-tag was
detected with monoclonal antibody YL1/2, which specifically rec-
ognizes this tag. Note the specific binding of M-protein fragment
Mp2–Mp3 to all myosin fragments that contain the central portion
of LMM (myosin heavy chain residues 1506–1674) but not to
LMM30 and LMM50–75.
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were purified in the native state as described in MA-
TERIALS AND METHODS. Phosphorylation was as-
sayed by incubation with [g-32P]ATP in the presence
of PKA, followed by SDS-PAGE and autoradiography.
Figure 5 shows that both normal Mp1–5 and the mu-
tant Mp1–5(Ser39Ala) were readily phosphorylated to
comparable levels, while the mutant Mp1–5(Ser76Ala)
and the double-mutant Mp1–5(Ser39, Ser76Ala) were
essentially nonreactive. To determine the stoichiome-
try of the phosphorylation, the amount of phosphate
incorporation into M-protein and the recombinant
protein fragments was compared by scintillation
counting. Again, only M-protein, “wild-type” Mp1–5,
and the mutant Mp1–5(Ser39Ala) were phosphory-
lated at the same level (0.97, 0.95, and 0.96 mol of
phosphate per mol of protein, respectively), while
both the other mutants were essentially negative (our
unpublished results). Thus, it seems that in the native
M-protein and in the fragment Mp1–5, serine 76 is the
only substrate for PKA.
Interaction of M-Protein with Myosin Is Modulated
by PKA Phosphorylation
Because the experiments described above delineate a
myosin-binding site located in proximity of a target
site for PKA (serine 76), we analyzed whether PKA
phosphorylation of M-protein influences the binding
to myosin. In the binding assays, a series of proteolytic
and recombinant myosin rod fragments were over-
layed with purified bovine M-protein before or after
PKA phosphorylation. Figure 6a shows that M-protein
bound to the myosin rod derivatives exactly as de-
scribed above for the proteolytic and recombinant
fragments (Figures 2 and 3). On the other hand, phos-
phorylation of M-protein by PKA almost completely
abolished the binding (Figure 6b).
Different myosin derivatives were also used to map
the M-protein–binding site on the rod portion of my-
osin at greater precision. While proteolytic myosin
rod, and proteolytic and recombinant LMM, as well as
LMM 59 and LMM 50, were recognized by M-protein,
LMM 50–75 and LMM 30 failed to bind M-protein
(Figure 6a). We therefore conclude that the M-protein–
binding site on the myosin heavy chain is confined to
the 169 amino acids between residues 1506 and 1674
located in the central part of LMM (numbers refer to
Figure 4. Phosphorylation of native M-protein and phosphoamino
acid analysis of M-protein and a recombinant Mp1–5 fragment. (A)
M-protein from bovine skeletal muscle (lane 1) and a limited digest
with trypsin (lane 2), analyzed on 4–12% SDS-PAGE (see MATERI-
ALS AND METHODS). (B) The corresponding autoradiograph of
the samples shown in panel A after incubation with PKA in the
presence of [g-32P] ATP shows that M-protein (lane 1) is readily
phosphorylated while its tryptic fragment (Mp6– Mp13) is not (lane
2). M 5 molecular mass standards in kilodaltons. (C) Phos-
phoamino acid analysis of native M-protein from bovine skeletal
muscle (lane 1) and the recombinant M-protein fragment Mp1–Mp5
(lane 2) after phosphorylation with PKA. Positions of marker amino
acids are indicated. Clearly, phosphorylation occurs in both samples
exclusively on serine residues.
Table 1. Phosphorylation of synthetic peptides by PKAa
Peptide sequence Apparent KM Vmax
LRRASLG 16 20.2 mmol min21 mg21
LKRASLG 1400 17.1 mmol min21 mg21
LRKASLG 260 16.9 mmol min21 mg21
LRRASLG 14 266.4 cpm/min
EKARLKSRPSAPWTGQ 532 130.9 cpm/min
LDEYASKKRASTQASSQ 993 42.0 cpm/min
RVCAKRVSTQEDEEQE 1027 66.5 cpm/min
a The upper part of the table lists apparent KM and Vmax values for
a well characterized peptide substrate (kemptide) for PKA (Kemp
et al., 1977) and two derivatives. The lower part summarizes our
measurements using kemptide, a peptide from myomesin (see
Obermann et al., 1996) and the two peptides from M-protein de-
scribed in this study. Phosphorylation reactions were carried out
as described in MATERIALS AND METHODS. Peptide sequences
are given in column 1.
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the amino acid sequence of rabbit fast skeletal muscle
myosin heavy chain; see Maeda et al., 1987).
Transfection of Cultured Cells
To identify the regions of M-protein required for the
incorporation of the molecule into the sarcomere, cul-
tured cells were transfected with a series of constructs
in the eukaryotic expression vector pCMV5-T7. The
pCMV vector results in strong, constitutive expression
of cDNAs in most eukaryotic cells under control of the
cytomegalovirus promoter (Andersson et al., 1989).
We replaced the original site for cloning foreign DNAs
by introducing, immediately adjacent to the start
codon, a new cassette containing recognition sites for
the restriction enzymes BamHI, MluI, HindIII, SalI, and
a sequence encoding the T7-tag, a 12-amino acid res-
idue epitope (Lutz-Freyermuth et al., 1990; Tsai et al.,
1992). Upon transfection, this results in the expression
of a recombinant protein bearing at its carboxy termi-
nus the T7-tag, which can be detected with a T7-tag–
specific monoclonal antibody.
The effect of overexpression of specific portions of
M-protein was studied mainly in BHK-21/C13 cells.
These cells, which can be routinely transfected with
high efficiency (;5–25%, depending on the transfected
construct), express already under certain culture con-
ditions several sarcomeric proteins that assemble into
myofibril-like structures (MLS). These resemble early
myofibrils in “classical” muscle cells (Schaart et al.,
1991; Van der Loop et al., 1996). Before the distribution
and the effect of the M-protein constructs were stud-
ied, their correct expression was verified. At 24–40 h
after transfection, cells were harvested in SDS-sample
buffer and analyzed by Western blotting. In each case
the T7 tag-specific antibody recognized a protein of
the expected size. In addition, the correct expression
was confirmed with domain-assigned antibodies for
most of the constructs (our unpublished results).
Transfected cells were induced to differentiate and
were inspected by immunofluorescence between 1
and 6 d later. To allow for a comparison with the
internal sarcomeric cytoskeletal structures, the local-
ization of T7-tagged proteins was usually compared
with that of an epitope of titin located close to the A/I
Figure 5. In vitro phosphorylation of mutant recombinant M-
protein fragments. Purified EEF-tagged Mp1–Mp5 fragments were
phosphorylated in vitro by PKA and 32P-labeled ATP and run on
two identical 4–10% gradient polyacrylamide gels. One gel was
blotted to nitrocellulose and stained with the antibody recognizing
the EEF-tag and a peroxidase-coupled secondary antibody (lanes
1–4), while the second gel was dried and autoradiographed (lanes
5–8). Lanes 1–4 contain approximately identical amounts of Mp1–
Mp5 (lane 1), Mp1–Mp5 (Ser39/Ala) (lane 2), Mp1–Mp5 (Ser76/
Ala) (lane 3), and Mp1–Mp5 (Ser39, 76/Ala) (lane 4). Lanes 5–8
show that Mp1–Mp5 and its (Ser39/Ala) mutant are phosphory-
lated, while phosphorylation of both mutants containing the Ser76/
Ala mutation (lanes 7 and 8) is almost completely abolished. Thus
Ser76 is the PKA phosphorylation site of M-protein.
Figure 6. Interaction of unphosphorylated and PKA phosphory-
lated M-protein with proteolytic and recombinant derivatives of
myosin. The same amounts (1 mg) of myosin-rod, proteolytic LMM,
LMM75, LMM59, LMM50, LMM30, LMM50–75, and ovalbumin,
serving as a control, were spotted on nitrocellulose filters and
overlayed with increasing concentrations (1 5 0.1 mM, 2 5 0.3 mM,
3 5 1.0 mM) of unphosphorylated (a) and phosphorylated (b) M-
protein. (c) is a control without protein. Binding of M-protein was
detected using the monoclonal M-protein antibody MpAA280 (see
Obermann, et al., 1996). Note that phosphorylation of M-protein
almost completely abolished binding to myosin derivatives.
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junction. Figure 7 (E–H) shows that the construct com-
prising domains Mp2–Mp3 is localized primarily
along MLS. In some cases, the recombinant protein
was also revealed in dispersed cytoplasmic aggre-
gates. In such cells, MLS were usually destroyed and
the recombinant protein was found to colocalize with
Figure 7. Expression of recombinant M-protein fragments in transiently transfected BHK-21/C13 cells. BHK-21/C13 cells transfected with
constructs encoding Mp2 (A and B), Mp3 (C and D), or Mp2–Mp3 (E–H) were double stained with T7-tag antibody to localize the recombinant
M-protein fragment (A, C, E, and G) and a titin antibody (B, D, F, and H). (A– D) Examples of transfected cells that contain large amounts
of diffusely distributed recombinant protein (A and C) and titin, which appears in a normal staining pattern (arrowheads in B and D). The
expressed Mp2–Mp3 construct either disrupts MLS, which then results in the appearance of numerous cytoplasmic aggregates containing
both the recombinant protein and titin (arrowheads in E and F), or colocalizes with MLS (arrowheads in G and H). For details see RESULTS.
Magnification, 10503.
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titin in these aggregates (Figure 7, E and F). In con-
trast, transfection with single domains (Mp2 contain-
ing the interdomain linker or Mp3) consistently re-
sulted in a diffuse distribution of the expressed
recombinant protein and a normal appearance of MLS
(Figure 7, A–D; see also Table 2).
When cells were transfected with a construct com-
prising the unique amino-terminal domain Mp1 in
addition to domains Mp2 and Mp3, the recombinant
protein was recovered essentially in the nucleus (our
unpublished results). A diffuse cytoplasmic distribu-
tion without obvious association with MLS was de-
tected upon transfection with constructs encoding do-
mains Mp4–Mp8 or Mp9–Mp13. In these cases we did
not observe any destructive effects on MLS or a neg-
ative effect on the ability of the cells to differentiate
(see Table 2).
To extend the results of the transfection studies with
BHK cells, we also transfected C2C12 mouse myo-
blasts. Similar to the situation in BHK cells, an obvious
colocalization of Mp2–Mp3 was found with nascent or
mature myofibrils (Figure 8, A–D), while other con-
structs (e.g., Mp4–Mp8) showed a diffuse cytoplasmic
localization (Table 2). Unlike in BHK cells, myofibril
structure seemed not affected (Figure 8, B, D, and E).
Surprisingly, Mp9–Mp13 was also distributed along
filaments in a regular and discontinuous punctate pat-
tern (Figure 8E). Inclusion of the head domain Mp1
into the construct Mp2–Mp3 typically resulted in a
nuclear localization of the recombinant protein. In the
few cases in which a cytoplasmic localization was also
observed, the protein colocalized with stress fiber-like
structures or myofibrils (Table 2). Both cell lines (BHK
and C2C12) were also transfected with Mp1–Mp5
and the constructs in which either Ser39 or Ser76
was mutated to Ala (see above). In general, trans-
fection efficiencies were very low in these experi-
ments, and all resulting recombinant proteins
showed almost exclusively nuclear localization (our
unpublished results).
DISCUSSION
M-protein is a prominent structural protein of sarco-
meric M bands in vertebrate fast and cardiac muscles
(Perriard, 1993). Together with myomesin and titin, it
forms the structures that cross-link myosin thick fila-
ments in the central bare zone. We therefore started to
search for binding sites between these proteins and
their possible regulation.
Both limited proteolysis of purified M-protein and
a series of recombinant constructs identified a my-
osin-binding site in domains Mp2–Mp3. Consistent
with earlier observations (Mani and Kay, 1978;
Woodhead and Lowey, 1983; Ba¨hler et al., 1985) we
found this interaction to be rather weak. It was best
documented in solid-phase overlay assays (Figures
2, 3, and 6). The location of the myosin-binding site
revealed an interesting difference between M-pro-
tein and myomesin, the second major structural pro-
tein of the M band. Although both proteins share the
same domain organization and exhibit ;50% iden-
tity over the repeat domains, their binding proper-
ties seem very different. Likewise, their structural
organization within the sarcomeric M band inferred
by immunoelectron microscopy is different (Ober-
mann et al., 1996). In myomesin the amino-terminal
domain My1 seems to harbor the myosin-binding
site (Obermann et al., 1997), while the subsequent
pair of Ig domains Mp2–Mp3 shows myosin binding
in the case of M-protein (Figure 3). In further exper-
iments it was not possible to attribute the myosin-
binding site to a single domain of M-protein. This
observation resembles the situation found for the
interactions of both myomesin and C-protein with
titin. In both cases, constructs consisting of at least
three domains were necessary to reveal binding of
titin (Freiburg and Gautel, 1996; Obermann et al.,
1997). Thus, it seems that the interactions of titin
with other cytoskeletal proteins of the Ig superfam-
ily binding arises by a combination of weak but






BHK-21/C13 C2C12 BHK-21/C13 C2C12 BHK-21/C13 C2C12
Mp2 2 2 2 2 2 2
Mp3 2 2 2 2 2 2
Mp2–Mp3 1 1 1 2 2 2
Mp1–Mp3 2 1 2 2 1 1
Mp4–Mp8 2 2 2 2 2 2
Mp9–Mp13 2 1 2 2 2 2
a BHK-21/C13 cells and C2C12 cells were transiently transfected with the M-protein constructs listed in column 1. Columns 2-7 give the
respective localization and/or the effect of each construct as analyzed by immunofluorescence microscopy. For details see RESULTS.
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cooperative interactions. It seems possible that a
similar situation also holds for the interaction of
M-protein and myosin.
Since the myosin-binding site of M-protein (Mp2
plus Mp3) is adjacent to the unique amino-terminal
domain Mp1 of the molecule, we investigated this
Figure 8. Expression of recombinant M-protein fragments in differentiating C2C12 cells. C2C12 cells transfected with constructs encoding
T7-tagged Mp2–Mp3 (A–D) or Mp9–Mp13 (E) were allowed to differentiate for 2 (E) or 6 (A to D) d, respectively. Subsequently they were
stained with T7-tag antibody (A, C, and E) and tetramethylrhodamine-5-isothiocyanate-labeled phalloidin (B) or MpAA259 (D) followed by
secondary antibody. Note that most of the expressed Mp2–Mp3 polypeptide associates with myofibrils (arrowheads in A–D). Transfection
with Mp9–Mp13 leads to expression of a polypeptide that binds to myofibrils in a periodic manner (arrowheads in E). For details see
RESULTS. Magnification, 10503.
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molecular region in more detail. Computer analysis of
the translated human M-protein cDNA sequence re-
vealed two potential target sites for cAMP-dependent
protein kinase A (Vinkemeier et al., 1993) in the pep-
tides KKRAS* (residues 35–39) and KRVS* (residues
73–76). Indeed, purified M-protein can be specifically
phosphorylated by PKA as well as by muscle extracts.
Phosphorylation is serine specific and involves the
amino-terminal domain Mp1 (Figure 4). Kinetic char-
acterization of synthetic peptides encompassing both
motifs demonstrated a KM value in the range of 23 of
that of a recently characterized PKA phosphorylation
site in myomesin (Table 1; Obermann et al., 1997). The
Vmax value is ; 50% of the same substrate. These
values are within the range of other target sequences
for PKA characterized previously (Pearson and Kemp,
1991). Analyses using recombinant M-protein frag-
ments, in which either one or both of these serine
residues were mutated to alanine, revealed that only
serine residue 76 can be phosphorylated by PKA (Fig-
ure 5). This indicates that the three-dimensional struc-
ture of domain Mp1 in the native M-protein molecule
allows reactivity with PKA exclusively for Ser76. This
result is made more significant by the finding that this
site is well conserved between chicken (Noguchi et al.,
1992) and human sequences (Vinkemeier et al., 1993).
The functional importance of this phosphorylation site
is indicated by the finding that it seems to control the
interaction of M-protein with myosin. Thus, while do-
mains Mp2–Mp3 bind constitutively to myosin LMM,
phosphorylation of Ser76 in the adjacent domain Mp1
modulates this binding. The phosphorylated fragment
essentially lacks myosin binding. This may indicate com-
plex changes of the three-dimensional structure of a
larger molecular region of M-protein as the result of Ser
76 phosphorylation.
Earlier biochemical data indicate that M-protein also
binds to titin (Nave et al., 1989). In our binding assays we
have not yet been able to identify a titin-binding site in
M-protein (our unpublished results). This is most likely
due to the fact that our constructs did not cover the
entire carboxy-terminal region of titin. In particular, the
500-residue insertion between Ig domains m3 and m4
(Gautel et al., 1993) was not included in the assay, since
it could not be produced as recombinant protein (Gautel,
personal communication). Our recent immunoelectron
microscopical data, however, predict that this region of
titin could be essential for M-protein binding (Obermann
et al., 1996).
This study also demonstrates that recombinant con-
structs of M-protein can be efficiently incorporated
into MLS after transient expression in differentiating
BHK-21/C13 cells. These MLS were shown to resem-
ble early myofibrils in standard differentiating muscle
cells but offer many advantages in the handling of cells
in culture and in their transfection efficiency (Schaart et
al., 1991; Van der Loop et al., 1996). Immunofluorescence
microscopy revealed that a construct comprising do-
mains Mp2–Mp3 localized primarily to MLS in trans-
fected cells (Figure 7 and Table 2). Thus it seems that the
myosin-binding site of M-protein is involved in the spe-
cific targeting in the myofibril. Similar observations were
made when C2C12 mouse myoblast cells were trans-
fected. While the construct Mp2–Mp3 was again found
in nascent myofibrils, the fragment Mp4–Mp8 was dis-
tributed diffusely in the cytoplasm (Figure 8 and Table
2). Interestingly, the construct Mp9–Mp13 was also re-
covered in myofibrils (Figure 8 and Table 2). This indi-
cates that in the carboxy-terminal third of M-protein,
another myofibrillar binding site, possibly a titin-binding
site (see above), can be expected.
The myosin-binding site in M-protein provides the
second example of a protein–protein interaction in the
sarcomeric M band whose binding status is controlled
by PKA phosphorylation. For myomesin, phosphoryla-
tion was shown to regulate the binding to titin (Ober-
mann et al., 1997). In both cases phosphorylation could
provide a mechanism that controls the events during
sarcomeric M band assembly, regeneration, and turn-
over in a spacial and temporal order. The binding of
M-protein to myosin could be a mechanism necessary to
provide a stronger thick filament association in myofi-
brils of fast and cardiac muscle fibers, since only these
fibers of the adult animal express M-protein.
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